Production (Stage)
EyePoint Pharmaceuticals, Inc.
EYPT
$9.03
$0.171.92%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -54.33% | -193.63% | -132.80% | -34.49% | -38.37% |
| Total Depreciation and Amortization | 64.03% | 316.96% | 254.78% | 174.24% | 188.57% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -49.79% | 96.13% | 55.15% | 85.41% | 332.07% |
| Change in Net Operating Assets | -1.36% | 91.06% | -148.45% | -95.68% | -1,109.45% |
| Cash from Operations | -70.41% | -55.13% | -156.70% | -135.39% | -85.16% |
| Capital Expenditure | 76.88% | 56.51% | 8.49% | -127.27% | -146.69% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 80.91% | -106.59% | -- | -1,250.51% | -32.45% |
| Cash from Investing | 89.97% | -103.53% | 1,041.63% | -1,291.02% | -35.16% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -87.00% | -30.40% | 11.76% | 12,400.00% | 1,738.71% |
| Repurchase of Common Stock | 72.04% | -- | -- | -- | -2,477.51% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -226.97% | -913.89% | 100.00% | 83.85% | -- |
| Cash from Financing | -926.96% | -30.57% | 14.78% | 100.90% | 102.25% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -41.91% | -86.59% | -66.70% | -632.76% | -201.16% |